Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.249
Filter
1.
Rev Assoc Med Bras (1992) ; 70(6): e20240045, 2024.
Article in English | MEDLINE | ID: mdl-39045962

ABSTRACT

OBJECTIVE: The objective of this study was to assess the clinical and uterine cervix characteristics of patients displaying vaginal discharge with positive results for Mycoplasma sp. and/or Ureaplasma spp. METHODS: An analytical cross-sectional study involving women aged 18-45 years was conducted. Microbiological assessments included Ureaplasma and Mycoplasma cultures, as well as human papillomavirus hybrid capture using ecto and endocervix swabs. All tests were two-tailed, and significance was set at p<0.05. RESULTS: Among 324 women, Ureaplasma prevalence was 17.9%, and Mycoplasma prevalence was 3.1%. The Ureaplasma-positive group exhibited a higher frequency of urinary tract infections (39.1 vs. 19%, p=0.002) and human papillomavirus (39.7 vs. 12.8%, p≤0.001) compared with controls. The Mycoplasma-positive group showed a higher frequency of non-contraceptive use compared with controls (66.2 vs. 30.0%, p=0.036). Abnormal colposcopic findings were more prevalent in the Mycoplasma/Ureaplasma-positive group than in controls (positive: 65% vs. control: 35%, p=0.001). Pap smear findings did not differ between the groups. CONCLUSION: Ureaplasma spp. was associated with urinary tract infections and human papillomavirus, while the presence of Mycoplasma sp. was linked to reduced contraceptive use. When analyzing both pathogens together, a higher frequency of abnormal colposcopic findings was observed, with no difference in cytological findings in the positive group.


Subject(s)
Cervix Uteri , Mycoplasma Infections , Mycoplasma , Ureaplasma Infections , Ureaplasma , Humans , Female , Adult , Ureaplasma Infections/microbiology , Ureaplasma Infections/epidemiology , Cross-Sectional Studies , Mycoplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Ureaplasma/isolation & purification , Young Adult , Middle Aged , Adolescent , Cervix Uteri/microbiology , Cervix Uteri/pathology , Mycoplasma/isolation & purification , Vaginal Discharge/microbiology , Prevalence , Papillomavirus Infections/microbiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/epidemiology , Brazil/epidemiology , Vaginal Smears
2.
J Clin Microbiol ; 62(7): e0022624, 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-38832769

ABSTRACT

Antimicrobial susceptibility testing (AST) of human mycoplasmas using microdilution is time-consuming. In this study, we compared the performance of MICRONAUT-S plates (Biocentric-Bruker) designed for AST of Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis with the results using the Clinical & Laboratory Standards Institute (CLSI) reference method. Then, we investigated the prevalence and mechanisms of resistance to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. The two methods were compared using 60 strains. For the resistance prevalence study, U. parvum-, U. urealyticum-, and M. hominis-positive clinical specimens were collected for 1 month each year in 22 French diagnostic laboratories. MICs were determined using the MICRONAUT-S plates. The tet(M) gene was screened using PCR, and fluoroquinolone resistance-associated mutations were screened using PCR and Sanger sequencing. Comparing the methods, 99.5% (679/680) MICs obtained using the MICRONAUT-S plates concurred with those obtained using the CLSI reference method. For 90 M. hominis isolates, the tetracycline, levofloxacin, and moxifloxacin resistance rates were 11.1%, 2.2%, and 2.2%, respectively, with no clindamycin resistance. For 248 U. parvum isolates, the levofloxacin and moxifloxacin resistance rates were 5.2% and 0.8%, respectively; they were 2.9% and 1.5% in 68 U. urealyticum isolates. Tetracycline resistance in U. urealyticum (11.8%) was significantly (P < 0.001) higher than in U. parvum (1.2%). No macrolide resistance was observed. Overall, the customized MICRONAUT-S plates are a reliable, convenient tool for AST of human mycoplasmas. Tetracycline and fluoroquinolone resistance remain limited in France. However, the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires monitoring. IMPORTANCE: Antimicrobial susceptibility testing of human urogenital mycoplasmas using the CLSI reference broth microdilution method is time-consuming and requires the laborious preparation of antimicrobial stock solutions. Here, we validated the use of reliable, convenient plates designed for antimicrobial susceptibility testing that allows the simultaneous determination of the MICs of eight antibiotics of interest. We then investigated the prevalence and mechanisms of resistance of each of these bacteria to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. We showed that the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires ongoing monitoring.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Microbial Sensitivity Tests , Mycoplasma Infections , Mycoplasma hominis , Ureaplasma Infections , Ureaplasma urealyticum , Ureaplasma , Humans , Mycoplasma hominis/drug effects , France/epidemiology , Ureaplasma/drug effects , Ureaplasma/genetics , Anti-Bacterial Agents/pharmacology , Ureaplasma Infections/microbiology , Ureaplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Mycoplasma Infections/epidemiology , Ureaplasma urealyticum/drug effects , Ureaplasma urealyticum/genetics , Prevalence , Fluoroquinolones/pharmacology , Macrolides/pharmacology
3.
Diagn Microbiol Infect Dis ; 110(1): 116394, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38850689

ABSTRACT

Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), Ureaplasma urealyticum (UU) are the common sexually transmitted pathogens and lead to genital diseases, highly prevalent all around the world. The objective of this study was to analyze the prevalence of NG, CT and UU among outpatients in central China. A total of 2186 urogenital swabs were collected from the patients and the NG, CT and UU pathogens were testing with RT-PCR method, meanwhile the medical records were obtained from the hospital information system. The overall infection rates of NG, CT and UU were 4.57 %, 6.63 % and 48.81 % respectively, showed the prevalence of UU was higher than NG and CT. The younger people had the highest infection rate of NG (10.81 %), CT (20.54 %) and UU (54.59 %). Single infection (89.09 %) was significant higher than co-infection (10.91 %), and the CT-UU co-infection was the prominent pattern (66.41 %). There were an obvious sex difference, the prevalence of NG and CT were significant higher in male, whereas UU was higher in female. Our study could contributed a better understanding of the prevalence of NG, CT and UU, facilitating to the development of effective screening, prevention and treatment policies.


Subject(s)
Chlamydia Infections , Chlamydia trachomatis , Gonorrhea , Neisseria gonorrhoeae , Outpatients , Ureaplasma Infections , Ureaplasma urealyticum , Humans , China/epidemiology , Female , Male , Chlamydia trachomatis/genetics , Chlamydia trachomatis/isolation & purification , Ureaplasma urealyticum/isolation & purification , Ureaplasma urealyticum/genetics , Adult , Prevalence , Retrospective Studies , Neisseria gonorrhoeae/isolation & purification , Neisseria gonorrhoeae/genetics , Ureaplasma Infections/epidemiology , Ureaplasma Infections/microbiology , Gonorrhea/epidemiology , Gonorrhea/microbiology , Chlamydia Infections/epidemiology , Chlamydia Infections/microbiology , Middle Aged , Outpatients/statistics & numerical data , Young Adult , Adolescent , Coinfection/epidemiology , Coinfection/microbiology , Aged
5.
Altern Ther Health Med ; 30(6): 96-102, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38743894

ABSTRACT

Objective: Ureaplasma spp. comprise a group of mycoplasmas containing two human-associated species, namely, Ureaplasma urealyticum (UUR) and Ureaplasma parvum (UPA). The characterization of Ureaplasma species as pathogens contributing to male infertility remains a subject of considerable controversy. While numerous authors have proposed a relationship between UUR and changes in fertility, there is limited evidence supporting the involvement of UPA in this context. There has been an increased focus on Ureaplasma spp. and its potential role in the development of male infertility, especially over the past few years. The review aims to clarify the relationship between Ureaplasma species and male infertility. Methods: Firstly, we introduce a background of the appropriate biology including growth characteristics, the divided biovars, and the transmission pathways. Secondly, we examine the studies that support a causal role for Ureaplasma spp. in the development of infertility in the last 30 years. Finally, the diagnosed method, antimicrobial susceptibility, and potential therapeutic considerations are evaluated. Results: UPA and UUR can impair semen motility. The species of Ureaplasma spp., the sexual history of the patient, the number of sexual partners, the load of Ureaplasma, and antimicrobial resistance are expected to constitute key risk factors in the development of male infertility. In terms of treatment, Doxycycline remains the drug of first choice for ureaplasmal infections. Conclusion: Ureaplasma spp. are not simply "innocent bystanders" in infertility and may indeed be an "underestimated enemy of human reproduction". Ureaplasma spp. can be considered an etiological agent in unexplained infertility and a useful marker.


Subject(s)
Infertility, Male , Ureaplasma Infections , Ureaplasma , Humans , Male , Infertility, Male/microbiology , Ureaplasma/pathogenicity , Ureaplasma Infections/microbiology , Ureaplasma Infections/drug therapy , Anti-Bacterial Agents/therapeutic use
6.
Int J Mol Sci ; 25(7)2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38612809

ABSTRACT

Chorioamnionitis is a risk factor for necrotizing enterocolitis (NEC). Ureaplasma parvum (UP) is clinically the most isolated microorganism in chorioamnionitis, but its pathogenicity remains debated. Chorioamnionitis is associated with ileal barrier changes, but colonic barrier alterations, including those of the mucus barrier, remain under-investigated, despite their importance in NEC pathophysiology. Therefore, in this study, the hypothesis that antenatal UP exposure disturbs colonic mucus barrier integrity, thereby potentially contributing to NEC pathogenesis, was investigated. In an established ovine chorioamnionitis model, lambs were intra-amniotically exposed to UP or saline for 7 d from 122 to 129 d gestational age. Thereafter, colonic mucus layer thickness and functional integrity, underlying mechanisms, including endoplasmic reticulum (ER) stress and redox status, and cellular morphology by transmission electron microscopy were studied. The clinical significance of the experimental findings was verified by examining colon samples from NEC patients and controls. UP-exposed lambs have a thicker but dysfunctional colonic mucus layer in which bacteria-sized beads reach the intestinal epithelium, indicating undesired bacterial contact with the epithelium. This is paralleled by disturbed goblet cell MUC2 folding, pro-apoptotic ER stress and signs of mitochondrial dysfunction in the colonic epithelium. Importantly, the colonic epithelium from human NEC patients showed comparable mitochondrial aberrations, indicating that NEC-associated intestinal barrier injury already occurs during chorioamnionitis. This study underlines the pathogenic potential of UP during pregnancy; it demonstrates that antenatal UP infection leads to severe colonic mucus barrier deficits, providing a mechanistic link between antenatal infections and postnatal NEC development.


Subject(s)
Chorioamnionitis , Ureaplasma Infections , Pregnancy , Sheep , Animals , Humans , Female , Infant, Newborn , Ureaplasma Infections/complications , Intestines , Causality , Mucus
7.
Future Microbiol ; 19(10): 867-875, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38629933

ABSTRACT

Aim: To study antimicrobial susceptibilities of genital mycoplasmas recovered from endocervical samples of reproductive-age, nonpregnant women (n = 8,336). Materials & methods: For isolation and susceptibility testing, the Mycoplasma IST2 kit was used. Results: As many as 2093 samples were positive for mycoplasmas. The vast majority (>96%) of Ureaplasma urealyticum remained susceptible to tetracycline, doxycycline, josamycin and pristinamycin, whereas susceptibility rates to azithromycin and fluoroquinolones were significantly decreased. Mycoplasma hominis exhibited high susceptibility rates to doxycycline, pristinamycin and josamycin (98.1-100%), while susceptibilities to tetracycline and fluoroquinolones were considerably lower. Conclusion: Doxycycline remained highly potent for treating mycoplasmas; nevertheless, susceptibilities to other antimicrobials were significantly diminished.


[Box: see text].


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Microbial Sensitivity Tests , Mycoplasma Infections , Mycoplasma hominis , Ureaplasma urealyticum , Humans , Female , Mycoplasma Infections/microbiology , Mycoplasma Infections/epidemiology , Mycoplasma Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Greece/epidemiology , Ureaplasma urealyticum/drug effects , Ureaplasma urealyticum/isolation & purification , Mycoplasma hominis/drug effects , Mycoplasma hominis/isolation & purification , Adult , Young Adult , Doxycycline/pharmacology , Mycoplasma/drug effects , Mycoplasma/isolation & purification , Cervix Uteri/microbiology , Ureaplasma Infections/microbiology , Ureaplasma Infections/epidemiology , Ureaplasma Infections/drug therapy , Fluoroquinolones/pharmacology , Josamycin/pharmacology , Middle Aged , Adolescent , Azithromycin/pharmacology , Tetracycline/pharmacology , Pristinamycin/pharmacology
8.
Reprod Sci ; 31(7): 1771-1780, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38509400

ABSTRACT

It is unknown if recurrent urinary tract infection in the gynecologic population is associated with Mycoplasma and Ureaplasma genitourinary infections. The purpose of this scoping review is to highlight the literature surrounding Mycoplasma and Ureaplasma infections in the setting of recurrent urinary tract infections in the gynecologic population. MEDLINE ALL and Embase were searched to retrieve articles published in or after 1950 through 2024. Studies included were those with adults over age 18, non-pregnant, diagnosed with recurrent urinary tract infection and concurrent genitourinary infection with Ureaplasma or Mycoplasma published in English. Study designs eligible were quantitative, qualitative, and mixed methods studies. Publication types were also extended to conference abstracts and unpublished data. 2 independent investigators systematically performed title/abstract screening and full-text review using standardized inclusion criteria. For disagreements in either title and abstracts or full-text articles, consensus was reached through discussion by the 2 screeners and/or a 3rd final adjudicator. Screening and data extraction were performed on Covidence, a web-based platform for systematic review management. There were 1170 studies identified before title and abstract screening. 26 full-text articles were reviewed for eligibility. Of these, 23 full-text studies were excluded. 3 studies met full inclusion criteria and data extraction was performed on these 3 studies. There were 2 additional studies included after identification via other methods. There is a need for more recent and robust studies examining the role of Ureaplasma and Mycoplasma genitourinary infections amongst gynecologic patients with recurrent urinary tract infections.


Subject(s)
Mycoplasma Infections , Mycoplasma , Recurrence , Ureaplasma Infections , Ureaplasma , Urinary Tract Infections , Female , Humans , Mycoplasma/isolation & purification , Mycoplasma Infections/diagnosis , Mycoplasma Infections/microbiology , Ureaplasma/isolation & purification , Ureaplasma Infections/microbiology , Ureaplasma Infections/diagnosis , Urinary Tract Infections/microbiology , Urinary Tract Infections/diagnosis
9.
BMJ Case Rep ; 17(3)2024 Mar 07.
Article in English | MEDLINE | ID: mdl-38453229

ABSTRACT

Infection in the immunocompromised patient is often challenging on multiple levels. It can be difficult to distinguish between manifestations of the underlying disease, infection or malignancy. Symptoms may be vague or even absent, deviations in the common inflammatory parameters discrete, imaging findings scarce and the causative microbe may be a true pathogen as well as opportunistic. Here, we report an immunosuppressed female in her late teens with a purulent meningitis due to Ureaplasma parvum-a very rare cause of infection in the central nervous system of adults. We wish to highlight the relevance of intracellular pathogens and the need to actively search for these microbes, especially when response to broad-spectrum antibiotic treatment is absent. Furthermore, we emphasise the need for adequate molecular microbial diagnostics in search of microbes that are difficult to identify by culture and where serology and antigen tests may be absent or unreliable due to immune suppression.


Subject(s)
Meningitis, Bacterial , Ureaplasma Infections , Adolescent , Female , Humans , Anti-Bacterial Agents/pharmacology , Central Nervous System , Immunocompromised Host , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/drug therapy , Ureaplasma , Ureaplasma Infections/complications , Ureaplasma Infections/diagnosis , Ureaplasma Infections/drug therapy
10.
J Infect Dev Ctries ; 18(2): 258-265, 2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38484352

ABSTRACT

INTRODUCTION: Mycoplasma hominis and Ureaplasma parvum have been recently linked to sexually transmitted diseases and other conditions. There are a limited number of studies conducted on South African pregnant women that have assessed the prevalence and risk factors for genital mycoplasmas. METHODOLOGY: This study included 264 HIV infected pregnant women attending the King Edward VIII antenatal clinic in eThekwini, South Africa. DNA was extracted using the PureLink Microbiome kit and pathogens were detected using the TaqMan Real-time PCR assays. The statistical data analysis was conducted in a freely available Statistical Computing Environment, R software, version 3.6.3 using the RStudio platform. RESULTS: The prevalence of M. hominis and U. parvum, was 215/264 (81.4%), and 203/264 (76.9%), respectively. In the M. hominis positive group, a significantly (p = 0.004) higher proportion, 80.5% tested positive for U. parvum infection when compared to 61.2% among the M. hominis negative. Of the U. parvum positive women, a significantly (p = 0.004) higher proportion of women (85.2%) tested positive for M. hominis when compared to 68.9% among the U. parvum negative. In the unadjusted and adjusted analysis, being M. hominis positive increased the risk for U. parvum by approximately 3 times more (p = 0.014) and 4-fold (p = 0.008), respectively. CONCLUSIONS: This study showed a significant link between M. hominis and U. parvum infection. To date, there are a limited number of studies that have investigated M. hominisbeing a risk factor for U. parvum infection. Therefore, the data presented in the current study now fills in this gap in the literature.


Subject(s)
Mycoplasma Infections , Ureaplasma Infections , Humans , Female , Pregnancy , Mycoplasma hominis , Pregnant Women , HIV , Mycoplasma Infections/epidemiology , Ureaplasma/genetics , Ureaplasma Infections/epidemiology , Ureaplasma urealyticum/genetics
11.
Biol Reprod ; 110(5): 971-984, 2024 May 09.
Article in English | MEDLINE | ID: mdl-38335245

ABSTRACT

Intrauterine infection is a significant cause of neonatal morbidity and mortality. Ureaplasma parvum is a microorganism commonly isolated from cases of preterm birth and preterm premature rupture of membranes (pPROM). However, the mechanisms of early stage ascending reproductive tract infection remain poorly understood. To examine inflammation in fetal (chorioamnionic) membranes we utilized a non-human primate (NHP) model of choriodecidual U. parvum infection. Eight chronically catheterized pregnant rhesus macaques underwent maternal-fetal catheterization surgery at ~105-112 days gestation and choriodecidual inoculation with U. parvum (105 CFU/mL, n =4) or sterile media (controls; n = 4) starting at 115-119 days, repeated at 5-day intervals until C-section at 136-140 days (term=167 days). The average inoculation to delivery interval was 21 days, and Ureaplasma infection of the amniotic fluid (AF) was undetectable in all animals. Choriodecidual Ureaplasma infection resulted in increased fetal membrane expression of MMP-9 and PTGS2, but did not result in preterm labor or increased concentrations of AF pro-inflammatory cytokines. However, membrane expression of inflammasome sensors, NLRP3, NLRC4, AIM2, and NOD2, and adaptor ASC (PYCARD) gene expression were significantly increased. Gene expression of IL-1ß, IL-18, IL-18R1  , CASPASE-1, and pro-CASPASE-1 protein increased with Ureaplasma infection. Downstream inflammatory genes MYD88 and NFκB (Nuclear factor kappa-light-chain-enhancer of activated B cells) were also significantly upregulated. These results demonstrate that choriodecidual Ureaplasma infection, can cause activation of inflammasome complexes and pathways associated with pPROM and preterm labor prior to microbes being detectable in the AF.


Subject(s)
Inflammasomes , Macaca mulatta , Ureaplasma Infections , Ureaplasma , Animals , Female , Pregnancy , Inflammasomes/metabolism , Disease Models, Animal , Chorion/metabolism , Extraembryonic Membranes/metabolism , Extraembryonic Membranes/microbiology , Decidua/metabolism , Decidua/microbiology , Pregnancy Complications, Infectious/microbiology
12.
Am J Reprod Immunol ; 91(1): e13803, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38282606

ABSTRACT

Ureaplasma parvum is a mycoplasma commonly associated with female reproductive pathologies, such as preterm birth and infertility. It can survive intracellularly and utilize exosomes to propagate infection and its virulence factors. This study explored the differential protein composition of exosomes derived from normal and U. parvum-infected cells. We also investigated the impact of U. parvum on exosome biogenesis in ectocervical epithelial cells. Ectocervical epithelial (ECTO) cells were infected with U. parvum, and immunocytochemical staining was performed using U. parvum-specific marker multiple banded antigen (mba) and exosome marker CD9. NanoLC-MS/MS analysis was conducted to identify differentially expressed proteins in exosomes. Ingenuity Pathway Analysis (IPA) was performed to identify affected canonical pathways and biological functions associated with the protein cargo of exosomes. Western blot analysis of ECTO cells validated the proteomic findings in ECTO cells. U. parvum exhibited colonization of ECTO cells and colocalization with CD9-positive intraluminal vesicles. Proteomic analysis revealed decreased protein abundance and distinct protein profiles in exosomes derived from U. parvum-infected ECTO cells. Differentially expressed proteins were associated with clathrin-mediated endocytosis and various signaling pathways indicative of infection, inflammation, and cell death processes. Additionally, U. parvum infection altered proteins involved in exosome biogenesis. In ECTO cells, U. parvum infection significantly decreased clathrin, ALIX, CD9, and CD63 and significantly increased TSG101, Rab5, Rab35, and UGCG. These findings contribute to our understanding of the infection mechanism and shed light on the importance of exosome-mediated communication in the pathophysiology of diseases affecting the cervix, such as cervicitis and preterm birth.


Subject(s)
Exosomes , Premature Birth , Ureaplasma Infections , Humans , Infant, Newborn , Female , Cervix Uteri , Proteomics , Tandem Mass Spectrometry , Ureaplasma/physiology , Epithelial Cells , Clathrin
13.
J Glob Antimicrob Resist ; 36: 13-25, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38016593

ABSTRACT

BACKGROUND: Mycoplasma and Ureaplasma spp. especially M. hominis, U. parvum, and U. urealyticum recognized as an important cause of urogenital infections. Sake of the presence of antibiotic resistance and a continuous rise in resistance, the treatment options are limited, and treatment has become more challenging and costlier. OBJECTIVES: Therefore, this meta-analysis aimed to estimate worldwide resistance rates of genital Mycoplasmas and Ureaplasma to fluoroquinolones (ciprofloxacin, ofloxacin, moxifloxacin, and levofloxacin) agents. METHODS: We searched the relevant published studies in PubMed, Scopus, and Embase from until 3, March 2022. All statistical analyses were carried out using the statistical package R. RESULTS: The 30 studies included in the analysis were performed in 16 countries. In the metadata, the proportions of ciprofloxacin, ofloxacin, moxifloxacin, and levofloxacin resistance in Mycoplasma and Ureaplasma urogenital isolates were reported 59.8% (95% CI 49.6, 69.1), 31.2% (95% CI 23, 40), 7.3% (95% CI 1, 31), and 5.3% (95% CI 1, 2), respectively. According to the meta-regression, the ciprofloxacin, ofloxacin, moxifloxacin, and levofloxacin rate increased over time. There was a statistically significant difference in the fluoroquinolones resistance rates between different continents/countries (P < 0.05). CONCLUSIONS: Based on the results obtained in this systematic review and meta-analysis we recommend the use of the newer group of fluoroquinolones especially levofloxacin as the first choice for the treatment of genital mycoplasmosis, as well as ofloxacin for the treatment of genital infections caused by U. parvum.


Subject(s)
Mycoplasma , Ureaplasma Infections , Urinary Tract Infections , Humans , Ureaplasma , Fluoroquinolones/pharmacology , Levofloxacin , Ureaplasma urealyticum , Moxifloxacin , Mycoplasma hominis , Microbial Sensitivity Tests , Ureaplasma Infections/drug therapy , Ciprofloxacin
14.
Am J Transplant ; 24(4): 641-652, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37657654

ABSTRACT

Mollicute infections, caused by Mycoplasma and Ureaplasma species, are serious complications after lung transplantation; however, understanding of the epidemiology and outcomes of these infections remains limited. We conducted a single-center retrospective study of 1156 consecutive lung transplants performed from 2010-2019. We used log-binomial regression to identify risk factors for infection and analyzed clinical management and outcomes. In total, 27 (2.3%) recipients developed mollicute infection. Donor characteristics independently associated with recipient infection were age ≤40 years (prevalence rate ratio [PRR] 2.6, 95% CI 1.0-6.9), White race (PRR 3.1, 95% CI 1.1-8.8), and purulent secretions on donor bronchoscopy (PRR 2.3, 95% CI 1.1-5.0). Median time to diagnosis was 16 days posttransplant (IQR: 11-26 days). Mollicute-infected recipients were significantly more likely to require prolonged ventilatory support (66.7% vs 21.4%), undergo dialysis (44.4% vs 6.3%), and remain hospitalized ≥30 days (70.4% vs 27.4%) after transplant. One-year posttransplant mortality in mollicute-infected recipients was 12/27 (44%), compared to 148/1129 (13%) in those without infection (P <.0001). Hyperammonemia syndrome occurred in 5/27 (19%) mollicute-infected recipients, of whom 3 (60%) died within 10 weeks posttransplant. This study highlights the morbidity and mortality associated with mollicute infection after lung transplantation and the need for better screening and management protocols.


Subject(s)
Lung Transplantation , Mycoplasma , Ureaplasma Infections , Humans , Adult , Retrospective Studies , Ureaplasma Infections/epidemiology , Ureaplasma Infections/etiology , Ureaplasma Infections/diagnosis , Lung Transplantation/adverse effects , Lung Transplantation/methods , Risk Factors
15.
Orthopedics ; 47(1): e52-e56, 2024.
Article in English | MEDLINE | ID: mdl-37276443

ABSTRACT

Postoperative deep infection is usually identified by microbial culture. However, frequent false-negative results have severely limited effective treatment. We report a rare case of intra-articular and paravertebral infection after total knee arthroplasty caused by Mycoplasma hominis and Ureaplasma urealyticum, with multiple negative microbial culture results. Eventually, the pathogens were identified using metagenomic high-throughput sequencing, and the patient was successfully treated with several "old" antibiotics. We analyze the clinical characteristics of this patient and systematically describe the application of high-throughput sequencing and antibiotics. [Orthopedics. 2024;47(1):e52-e56.].


Subject(s)
Arthroplasty, Replacement, Knee , Mycoplasma Infections , Ureaplasma Infections , Humans , Mycoplasma Infections/drug therapy , Arthroplasty, Replacement, Knee/adverse effects , Ureaplasma Infections/drug therapy , Ureaplasma urealyticum , Anti-Bacterial Agents/therapeutic use , Postoperative Complications
16.
Eur J Clin Microbiol Infect Dis ; 42(12): 1425-1437, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37843646

ABSTRACT

BACKGROUND: Ureaplasma species are common pathogens of the urogenital tract and can cause a range of diseases. Unfortunately, there is still a scarcity of large-scale and cross-sectional studies on the prevalence of Ureaplasma species in China to clarify their epidemic patterns. METHODS: This study retrospectively analyzed the data of 18667 patients who visited Peking Union Medical College Hospital for showing various symptoms of (suspected) Ureaplasma species infection during the period 2013-2022. The overall prevalence of Ureaplasma species was calculated, and subgroup analyses were conducted in view of gender, age, specimen types, and diagnosis in every year within the period studied. Furthermore, previous literature that reported on the prevalence of Ureaplasma species in various regions of China was searched and summarized. RESULTS: The overall positive rate of Ureaplasma species in this study reached 42.1% (7861/18667). Specifically, the prevalence of Ureaplasma species was significantly higher in female patients, while the highest detection rate was found in the 21-50 age group. From 2013 to 2022, there were no significant differences in positive rates of Ureaplasma species among years. However, the detection rate of Ureaplasma species was decreased in COVID-19 period (2020-2022) compared to pre-COVID-19 period (2017-2019). In view of the distribution of patients, outpatients predominated, but the detection rate was lower than inpatients. Urine was the most common specimen type, while cervical swabs had the highest detection rate of Ureaplasma species. When grouped by diagnosis, the highest positive rate of Ureaplasma species was seen in patients with adverse pregnancy outcomes and the lowest rate in patients with prostate disease. The previous literature, although heterogeneous, collectively suggested a high prevalence of Ureaplasma species in China. CONCLUSIONS: Our study has shown that Ureaplasma species have reached a significant prevalence in China and demands adequate attention.


Subject(s)
COVID-19 , Mycoplasma Infections , Ureaplasma Infections , Male , Pregnancy , Humans , Female , Ureaplasma , Retrospective Studies , Prevalence , Tertiary Care Centers , Cross-Sectional Studies , Mycoplasma Infections/microbiology , Mycoplasma hominis , Ureaplasma Infections/epidemiology , Ureaplasma Infections/microbiology , Ureaplasma urealyticum
17.
BMJ Case Rep ; 16(9)2023 Sep 26.
Article in English | MEDLINE | ID: mdl-37751973

ABSTRACT

Infections caused by Ureaplasma urealyticum in immune-competent people are typically simple and uncomplicated. However, in cases of immunosuppression, severe disseminated infections can occur.This case report describes the case of a severe, disseminated infection caused by U. urealyticum in a young female with unacknowledged humoral immunosuppression due to treatment with ocrelizumab for multiple sclerosis.The patient was admitted due to a recurrent episode of a tubo-ovarian abscess. Throughout the following 2 months of hospitalisation, treatment with several types of antibiotics and the placement of various drains led to no improvement. As extensive investigations indicated hypogammaglobulinaemia, U. urealyticum was suspected, and tests came back positive. Treatment with doxycycline and moxifloxacin led to a full recovery.This demonstrates how humoral immunosuppression is a risk factor for severe disseminated infections and how these may be avoided through monitoring of immunoglobulin levels in patients treated with ocrelizumab.


Subject(s)
Agammaglobulinemia , Ureaplasma Infections , Humans , Female , Ureaplasma urealyticum , Agammaglobulinemia/chemically induced , Agammaglobulinemia/drug therapy , Anti-Bacterial Agents/adverse effects , Doxycycline/adverse effects , Ureaplasma Infections/diagnosis , Ureaplasma Infections/drug therapy
18.
Ann Clin Microbiol Antimicrob ; 22(1): 70, 2023 Aug 10.
Article in English | MEDLINE | ID: mdl-37563660

ABSTRACT

BACKGROUND: The emergence of multidrug-resistant (MDR) strains of genital pathogens, notably Mycoplasma genitalium and Ureaplasma spp., constitutes a significant global threat today. The present study aimed to evaluate the prevalence and trend of changes in MDR mycoplasma and ureaplasma strains. METHODS: An exhaustive search was performed across the ISI Web of Science, PubMed, Scopus, ScienceDirect, and Google Scholar databases to accumulate relevant studies without restrictions until April 2023. We used event rate and corresponding 95% confidence intervals to determine the frequency of resistance-related mutations and examine the trend of antibiotic resistance changes. RESULTS: The data from 27 studies, including 24,662 patients across 14 countries, were evaluated. Out of the total studies, 20 focused on M. genitalium infections, and five on Ureaplasma spp. The frequency of resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones in clinical strains of M. genitalium was 43.5%, 13.1%, and 18.6%, respectively. The prevalence of M. genitalium strains with double resistance and MDR was 11.0% and 17.4%, respectively. The incidence of both double-drug-resistant and MDR strains was higher in the World Health Organization (WHO) Western Pacific Region than in European and American populations. For Ureaplasma strains, resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones were 40.8%, 25.7%, and 90.3%, respectively. The rate of antibiotic resistance was higher in the African population compared to the European and WHO Western Pacific Regions. The rate of MDR Ureaplasma infections was 13.2%, with a higher incidence in the African population compared to the WHO Western Pacific and European regions. CONCLUSION: The proliferation and spread of MDR Mycoplasma and Ureaplasma strains present a significant public health challenge. The situation is indeed alarming, and the rising trend of MDR M. genitalium and MDR Ureaplasma infections suggests that therapies involving macrolides and fluoroquinolones may become less effective.


Subject(s)
Mycoplasma Infections , Mycoplasma , Ureaplasma Infections , Humans , Mycoplasma Infections/epidemiology , Ureaplasma Infections/epidemiology , Ureaplasma Infections/drug therapy , Mycoplasma hominis , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Ureaplasma/genetics , Fluoroquinolones/pharmacology , Tetracyclines/pharmacology , Macrolides/pharmacology , Mutation , Prevalence
19.
BMC Pulm Med ; 23(1): 229, 2023 Jun 26.
Article in English | MEDLINE | ID: mdl-37365524

ABSTRACT

BACKGROUND: It is unclear whether Ureaplasma-associated pneumonia and azithromycin treatment affect the risk for bronchopulmonary dysplasia (BPD). METHODS: A retrospective cohort study was performed in very low birth weight (VLBW) infants who tested positive for Ureaplasma within 72 h after birth in a tertiary unit. Chest X-ray (CXR) and laboratory test were performed before and after azithromycin treatment. Multivariate logistic regression analysis was used to identify the independent association between BPD and Ureaplasma-associated pneumonia, as well as BPD and effective azithromycin treatment. RESULTS: A total of 118 infants were included in the current study, of whom 36 developed BPD (defined as supplemental oxygen needed at postmenstrual age 36 weeks or discharge). The rate of BPD was significantly higher in infants with Ureaplasma-associated pneumonia (44.6%) compared to infants with Ureaplasma colonization (17.7%, P = 0.002). After adjusting for confounders, an effective azithromycin treatment was significantly associated with reduced risk of BPD [odd ratio (OR) 0.011; 95% confidence interval (CI): 0.000-0.250), whereas Ureaplasma-associated pneumonia was not significantly associated with BPD (OR 1.835; 95% CI: 0.548-6.147). CONCLUSION: Effective Azithromycin treatment in Ureaplasma positive VLBW infants was associated with a reduced risk of BPD.


Subject(s)
Bronchopulmonary Dysplasia , Ureaplasma Infections , Infant, Newborn , Humans , Infant , Azithromycin/therapeutic use , Bronchopulmonary Dysplasia/epidemiology , Infant, Premature , Ureaplasma , Cohort Studies , Retrospective Studies , Ureaplasma Infections/complications , Ureaplasma Infections/drug therapy
20.
Pediatr Transplant ; 27(5): e14538, 2023 08.
Article in English | MEDLINE | ID: mdl-37149734

ABSTRACT

BACKGROUND: The risk of infection following kidney transplant increases substantially in the setting of hypogammaglobulinemia and T-cell-depleting therapy. Ureaplasma has been described to cause invasive disease in immunocompromised hosts with humoral immunodeficiency. We describe a kidney transplant recipient with history of antineutrophil cytoplasmic autoantibody (ANCA) vasculitis remotely treated with rituximab who developed Ureaplasma polyarthritis following transplant. The purpose of this report is to highlight the unique risks that kidney transplant patients face particularly if hypogammaglobulinemic. CASE REPORT: Patient is a 16-year-old female with history of granulomatosis with polyangiitis (GPA) treated with maintenance dose of rituximab 13 months prior to transplant. Patient underwent deceased donor kidney transplant with thymoglobulin induction. IgG was 332 mg/dL and CD20 was zero at the time of transplant. One month posttransplant, the patient developed polyarticular arthritis without fever, pyuria, or evidence of GPA reactivation. MRI had diffuse tenosynovitis, myositis, fasciitis, cellulitis, and effusions of three involved joints. Bacterial, fungal, and AFB cultures remained negative, but 16 s ribosomal PCR testing from joint aspirates detected Ureaplasma parvum. The patient was treated with levofloxacin for 12 weeks with the resolution of symptoms. CONCLUSIONS: Ureaplasma infection is an under-recognized pathogen in kidney transplant patients. A high index of clinical suspicion should be employed to identify Ureaplasma infection, especially in those with secondary hypogammaglobulinemia, as this is often missed due to its lack of growth on standard media and the need for molecular testing. In patients with prior B-cell depletion, routine monitoring for B-cell recovery to identify risk factors for opportunistic infections is indicated.


Subject(s)
Agammaglobulinemia , Arthritis , Kidney Transplantation , Ureaplasma Infections , Female , Humans , Adolescent , Rituximab/therapeutic use , Kidney Transplantation/adverse effects , Agammaglobulinemia/complications , Ureaplasma , Ureaplasma Infections/complications , Ureaplasma Infections/diagnosis , Ureaplasma Infections/drug therapy , Arthritis/complications , Arthritis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL